Autologous stem cell transplantation in refractory Crohn’s disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study-Reference-Cited by-同舟云学术

Autologous stem cell transplantation in refractory Crohn’s disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study

Published:2019-05-31 Issue:1 Volume:19 Page:
ISSN:1471-230X
Container-title:BMC Gastroenterology
language:en
Short-container-title:BMC Gastroenterol

Author:

Snowden John A., ,Hawkey Chris,Hind Daniel,Swaby Lizzie^ORCID,Mellor Katie,Emsley Richard,Mandefield Laura,Lee Ellen,Badoglio Manuela,Polge Emmanuelle,Labopin Myriam,Gribben John,Pockley A. Graham,Foulds Gemma A.,Lobo Alan,Travis Simon,Parkes Miles,Satsangi Jack,Papaioannou Diana,Lindsay James O.,

Funder

Efficacy and Mechanism Evaluation Programme

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12876-019-0992-2.pdf

Reference22 articles.

1. Torres J, Mehandru S, Colombel J, Peyrin-biroulet L. Seminar Crohn’s disease. Lancet. 2017;389:1741–55.

2. van der Valk M, Mangen M, Severs M, van der Have M, Dijkstra G, van Bodegraven A, et al. Evolution of costs of inflammatory bowel disease over two years of follow-up. PLoS One. 2016;11(4):e0142481.

3. van der Valk ME, Mangen M-JJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014;63(1):72–9.